BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant,  Roche  Registration  Limited,  submitted  on  23  September  2002  an  application  for 
Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) 
for  Fuzeon  (enfuvirtide),  through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  21 
February 2002, this medicinal product has been referred to Part B of the Annex to Council Regulation 
No (EEC) 2309/93 of 22 July 1993 as amended. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr Per Nilsson 
Co-Rapporteur:  Prof Beatrix Silva-Lima 
Scientific Advice: 
The  applicant  received  Scientific  Advice  from  the  CPMP  on  25  May  2000,  16  November  2000  and 
15 December 2000. The Scientific Advice pertained to part II, III and IV of the dossier.  
Licensing status: 
The  product  was  not  licensed  in  any  country  at  the  time  of  submission  of  the  application. 
Fuzeon was licensed in the United States on 13 March 2003. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The applicant submitted to the CPMP a request for an accelerated procedure dated 11 July 2002 
according  to  the  CPMP  guidance  on  “accelerated  evaluation  of  products  indicated  for  serious 
diseases 
rev.1  dated 
18 September 2001.  The  CPMP,  during  its  23-25  July  2002  meeting,  agreed  to  consider  the 
possibility to adopt rapidly an opinion based on the recommendation of the Rapporteur and Co-
rapporteur in their respective Assessment Reports.  
(life-threatening  or  heavy  disabling  diseases),  CPMP/495/96” 
The procedure started on 21 October 2002. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on 
27 December 2002.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP 
members on 7 January 2003. 
During the meeting on 18-20 February 2003, the CPMP agreed to accelerate the procedure and 
adopted a consolidated List of Questions to be sent to the applicant. The final consolidated List 
of Questions was sent to the applicant on 20 February 2003. 
The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 
27 February 2003. 
The  Rapporteurs  circulated  an  Assessment  Report  on  the  applicant’s  responses  to  the  List  of 
Questions to all CPMP members on 7 March 2003. 
The  Rapporteurs  circulated an  updated  Assessment  Report  on the applicant’s  responses  to  the 
List of Questions to all CPMP members on 14 March 2003. 
During  the  CPMP  meeting  on  18-19  March  2003,  the  CPMP  agreed  on  a  list  of  outstanding 
issues  which  were  addressed  by  the  applicant  during  a  hearing  before  the  CPMP  held  on  19 
March 2003. 
The  CPMP,  in  the  light  of  the  overall  data  submitted  and  the  scientific  discussion  within  the 
Committee, issued a positive opinion for granting a Marketing Authorisation under exceptional 
circumstances to Fuzeon on 19 March 2003. The applicant provided on 19 March 2003 a letter 
of  undertaking  on  the  Specific  Obligations  and  Follow-up  measures  to  be  fulfilled  post-
authorisation. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 27 May 2003. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
